University of Southern California-ko ikertzaileekin lankidetzan egindako argitalpenak (3)

2020

  1. Potent cell-cycle inhibition and upregulation of immune response with abemaciclib and anastrozole in Neomonarch, phase II neoadjuvant study in HR+/HER2- Breast cancer

    Clinical Cancer Research, Vol. 26, Núm. 3, pp. 566-580

2016

  1. Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial

    Annals of Oncology, Vol. 27, Núm. 6, pp. 1041-1047

2011

  1. Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial

    Journal of Clinical Oncology, Vol. 29, Núm. 29, pp. 3877-3884